Defence Therapeutics Inc. / CA24463V1013
17.04.2024 - 08:00:03DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
| Defence Therapeutics Inc. / Key word(s): Financing 17.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH (“FMS”), a European corporate financing consulting firm, was commissioned by Defence to execute on a financing strategy for the Company. “Defence’s successful technology development has advanced the Company to becoming a clinical stage oncology company. To advance our growth, Defence secures a strong financial European based advisor experienced in the biotech field. Defence’s lead technology, the Accum® platform, has proven to be a broad and effective cancer killing technology for multiple indications and applications including ADCs, cancer vaccines and anti cancer injectable drugs,” says Mr. Plouffe, CEO and president of Defence. About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases. For further information: Sebastien Plouffe, President, CEO and Director P: (514) 947-2272 Splouffe@defencetherapeutics.comwww.defencetherapeutics.com Cautionary Statement Regarding “Forward-Looking” Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. 17.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Defence Therapeutics Inc. |
| 1680 - 200 Burrard St | |
| V6C3L6 Vancouver | |
| Canada | |
| E-mail: | info@defencetherapeutics.com |
| Internet: | https://defencetherapeutics.com |
| ISIN: | CA24463V1013 |
| WKN: | A3CN14 |
| Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
| EQS News ID: | 1882095 |
| End of News | EQS News Service |
| |
